Life sciences

Power new drug discovery, accelerate your time to market for medical devices and implants, and clear post-market surveillance with higher-quality RWD.

Testimonial

“Working with the OneMedNet team, we were able to access precisely curated clinical data, which was crucial for our research and development initiatives. The responsiveness and expertise of the OneMedNet team have significantly enhanced our capabilities, allowing us to leverage regulatory-grade clinical data with ease.”

No name, title, or company attribution is shown on the page for this quote.

Pave a smoother path to market

Curated, real-time and regulatory-grade real-world data (RWD) can expedite the clinical trial process — getting your solutions to the people who need them faster and with fewer hurdles.

RWD for drug development

RWD can help identify and validate new drug targets and assess unmet needs in the market. You may have used it in the past, only to find yourself sifting through petabytes of unstructured data.

Whether you take advantage of our partner network or provide us with previously acquired datasets, OneMedNet’s expert curation process delivers RWD that matches your precise cohort specifications exactly. You’ll add confidence to your journey from discovery to post-market surveillance.

RWD for medical devices and implants

Medical device and implant manufacturers need high-quality patient data to help develop new solutions and validate complication rates, removal and revision incidences, infection rates, and time to union.

OneMedNet’s real-time RWD gives you near on-demand access to your cohorts, with full longitudinal records to equip you with the ongoing insight you need to continue innovating new devices and continually validate those already in the market.

CASE STUDY

How our RWD fueled one company's cancer research

Our customer wanted to track the performance of three drugs already in-market, all used to treat metastatic melanoma.

THEIR SPECIFICATIONS
They requested data that would give them broad evidence around the performance of three of their key drugs in the marketplace. They wanted to not only track efficacy, but also side effects and the reasons behind why some patients stopped treatment.
The customer had made requests from other data providers in the past, but were unsatisfied by the low level of depth and rigor.
OUR PROCESS
We offered curated, retrospective data spanning 3 years to give the full picture of drug efficacy and treatment plans.
Our curation experts confirmed the results was highly tailored RWD with exact matches for cohort specifications.
THE RESULT
We provided complete patient treatment records, including electronic health record and treatment records, that perfectly matched the customer specifications. With this info, the organization was able to ensure satisfactory drug performance and to fuel future innovation of better performing drugs.

3 years

curated, retrospective data span

three drugs

already in-market, used to treat metastatic melanoma